FICZ and ITE significantly inhibited the frequency of IL-17-expressing CD4+T cells in both BD patients and in the controls, whereas no detectable effect was observed on the percentage of IFN-γ-expressing CD4+T cells (Figure 2). The gene discussed is IL17A; the disease is Behcet disease.